Clairvoyant Therapeutics

Topline data readout for CLA-PSY-201 Phase IIb (n=154)

Why it matters: Results from one of the largest randomized psilocybin AUD trials globally. If positive, Clairvoyant would be positioned for conditional market authorization in Canada (2025 target) and EU (2026 target). Topline data has been delayed multiple times — no public confirmation of release as of April 2026.

Watch next: Data publication; Phase 3 pivotal trial planning; Series A close

Actual: Nov 1, 2022

First patient dosed in Phase 2 trial in Canada

Why it matters: Clairvoyant launched one of the largest randomized psilocybin trials for AUD globally (ultimately 154 subjects). Two dosing sessions at weeks 5 and 9 combined with Motivational Enhancement Therapy (MET) — a well-validated behavioral framework for AUD.

Actual: Jan 1, 2023

First patient dosed in Europe (Phase 2b); trial upgraded from Phase 2 to Phase 2b designation

Why it matters: Multi-country EU + Canada trial generates regulatory-grade data for two major markets simultaneously. Finnish regulatory approval was among the first EU approvals for a psilocybin interventional trial.

Actual: Apr 1, 2024

90% randomization reached (>115 of original 128 target; later expanded to 154 subjects)

Why it matters: Rapid enrollment in a psychedelic trial of this size demonstrates strong investigator and patient interest. Expansion from 128 to 154 subjects increases statistical power.

Actual: Sep 6, 2024

Psyence Biomed announced $500K acquisition term sheet for Clairvoyant

Why it matters: Psyence Biomed sought to acquire Clairvoyant at a remarkably low valuation ($500K) for a company running a 154-patient Phase IIb trial — suggesting Clairvoyant was facing funding pressure.

Actual: Oct 1, 2024

Psyence Biomed halts Clairvoyant acquisition; Clairvoyant remains independent

Why it matters: Deal collapse leaves Clairvoyant independent but potentially underfunded. Series A financing was reportedly underway as of April 2024.